NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on November 7, 2024 and will host a conference call beginning at 4:30 p.m. Eastern time.
Conference Call & Webcast Details
| Date: | Thursday, November 7th |
| Time: | 4:30 p.m. Eastern time |
| Toll-Free Dial-In: | 800-717-1738 |
| International Dial-In: | 646-307-1865 |
| Conference ID: | 73461 |
| Live & Archived Webcast: | Link |
About LifeMD, Inc.
LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women's health, weight management, and hormone therapy. The Company leverages a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
Investor Contact
Marc Benathen, Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Jessica Friedeman, Chief Marketing Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.57 |
| Daily Change: | -0.17 -2.96 |
| Daily Volume: | 748,606 |
| Market Cap: | US$235.000M |
November 07, 2024 November 06, 2024 October 23, 2024 September 19, 2024 August 07, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
